m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02770)
Name
GW-2331
Synonyms
190844-95-2; PPAR ligand, Glaxo Wellcome
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
C27H36F2N2O4
InChI
1S/C27H36F2N2O4/c1-4-6-7-8-9-17-31(26(34)30-24-15-12-21(28)19-23(24)29)18-16-20-10-13-22(14-11-20)35-27(3,5-2)25(32)33/h10-15,19H,4-9,16-18H2,1-3H3,(H,30,34)(H,32,33)/t27-/m0/s1
InChIKey
VGSJXSLGVQINOL-MHZLTWQESA-N
PubChem CID
657048
TTD Drug ID
D01POG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor alpha (PPARA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [4]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). [2], [4]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for GW-2331. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [2], [5]
References
Ref 1 Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m(6)A RNA Methylation. Front Pharmacol. 2020 Dec 18;11:568006. doi: 10.3389/fphar.2020.568006. eCollection 2020.
Ref 2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 3 A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014 Feb;10(2):93-5. doi: 10.1038/nchembio.1432. Epub 2013 Dec 6.
Ref 4 Circadian Clock Regulation of Hepatic Lipid Metabolism by Modulation of m(6)A mRNA Methylation. Cell Rep. 2018 Nov 13;25(7):1816-1828.e4. doi: 10.1016/j.celrep.2018.10.068.
Ref 5 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.